Literature DB >> 32960701

Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Zaikuan J Yu1, Eric P Mosher1, Namandjé N Bumpus1.   

Abstract

Antiretroviral therapy has markedly reduced morbidity and mortality for persons living with human immunodeficiency virus (HIV). Individual tailoring of antiretroviral regimens has the potential to further improve the long-term management of HIV through the mitigation of treatment failure and drug-induced toxicities. While the mechanisms underlying anti-HIV drug adverse outcomes are multifactorial, the application of drug-specific pharmacogenomic knowledge is required in order to move toward the personalization of HIV therapy. Thus, detailed understanding of the metabolism and transport of antiretrovirals and the influence of genetics on these pathways is important. To this end, this review provides an up-to-date overview of the metabolism of anti-HIV therapeutics and the impact of genetic variation in drug metabolism and transport on the treatment of HIV. Future perspectives on and current challenges in pursuing personalized HIV treatment are also discussed.

Entities:  

Keywords:  HIV medication; drug metabolism; drug-drug interactions; personalized medicine; pharmacogenomics

Mesh:

Substances:

Year:  2020        PMID: 32960701      PMCID: PMC7790910          DOI: 10.1146/annurev-pharmtox-021320-111248

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  139 in total

1.  Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Authors:  Pere Domingo; M Carmen Cabeza; Alain Pruvost; Ferran Torres; Juliana Salazar; M del Mar Gutierrez; M Gracia Mateo; Angels Fontanet; Irene Fernandez; Joan C Domingo; Francesc Villarroya; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.

Authors:  M B Faletto; W H Miller; E P Garvey; M H St Clair; S M Daluge; S S Good
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity.

Authors:  Alexandra M M Antunes; Ana L A Godinho; Inês L Martins; Gonçalo C Justino; Frederick A Beland; M Matilde Marques
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

4.  Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Authors:  Rosa I Sanchez; Kerry L Fillgrove; Ka Lai Yee; Yuexia Liang; Bing Lu; Aditya Tatavarti; Rachael Liu; Matt S Anderson; Martin O Behm; Li Fan; Yun Li; Joan R Butterton; Marian Iwamoto; Sauzanne G Khalilieh
Journal:  Xenobiotica       Date:  2018-03-28       Impact factor: 1.908

5.  Mechanism of indinavir-induced hyperbilirubinemia.

Authors:  S D Zucker; X Qin; S D Rouster; F Yu; R M Green; P Keshavan; J Feinberg; K E Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

6.  A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Authors:  Matt S Anderson; Sauzanne Khalilieh; Ka Lai Yee; Rachael Liu; Li Fan; Matthew L Rizk; Vedangi Shah; Azra Hussaini; Ivy Song; Lisa L Ross; Joan R Butterton
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

7.  Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

Authors:  G Ahluwalia; D A Cooney; N R Hartman; H Mitsuya; R Yarchoan; A Fridland; S Broder; D G Johns
Journal:  Drug Metab Dispos       Date:  1993 Mar-Apr       Impact factor: 3.922

8.  Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.

Authors:  Julie M Lade; Lindsay B Avery; Namandjé N Bumpus
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

9.  Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.

Authors:  Anne-Sophie Bélanger; Patrick Caron; Mario Harvey; Peter A Zimmerman; Rajeev K Mehlotra; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-06-01       Impact factor: 3.922

10.  Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes.

Authors:  Christine Lin; Julianne Shi; Amanda Moore; Salman R Khetani
Journal:  Drug Metab Dispos       Date:  2015-10-09       Impact factor: 3.922

View more
  1 in total

1.  Pharmacogenetics of HIV therapy: State of the art in Latin American countries.

Authors:  Camila de Almeida Velozo; Flávia Rachel Moreira Lamarão; Lucia Elena Alvarado-Arnez; Cynthia Chester Cardoso
Journal:  Genet Mol Biol       Date:  2022-09-30       Impact factor: 2.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.